Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123456»
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Dual therapies as a treatment of human immunodeficiency virus : the end of a paradigm ? (Pubmed Central) -  Sep 11, 2021   
    In the past, some dual therapies were associated with a higher risk of selecting resistance mutations. Nevertheless, current and future dual regimens based on powerful drugs with a high genetic barrier are non-inferior to triple therapies and could become the future gold standard for HIV treatment.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Cabenuva®: Differentiated service delivery and the community Pharmacists' roles in achieving UNAIDS 2030 target in Nigeria. (Pubmed Central) -  Aug 20, 2021   
    It is therefore recommended that the Nigerian government embrace community pharmacy-led drug administration initiatives and embark on accredited training programmes for the profession in line with drug administration services. The government should also put in place necessary funding mechanisms for community pharmacists for the extra workload placed on them in administering injection drug formulation in their respective pharmacies.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    New P4 trial:  GLACIER: Study Using CABENUVA (clinicaltrials.gov) -  Jul 28, 2021   
    P4,  N=120, Not yet recruiting, 
  • ||||||||||  Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection. (Pubmed Central) -  Jul 14, 2021   
    Providing PLWH and healthcare providers with novel modes of ART administration, enhancing individualisation of treatment, may facilitate the achievement of UNAIDS 95-95-95 objectives. No abstract available
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. (Pubmed Central) -  Jun 30, 2021   
    Our modelling suggests that injectable cabotegravir-rilpivirine offers potential benefits; however, to be a cost-effective option, its introduction might need to be carefully targeted to individuals with HIV who might otherwise have suboptimal adherence to ART. As data accumulate from trials and implementation studies, such findings can be incorporated into the model to better inform on the full consequences of policy alternatives.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Review, Journal:  Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. (Pubmed Central) -  Jun 22, 2021   
    Cabenuva™ is recently approved by Health Canada containing LA cabotegravir+LA rilpivirine nanocrystals (ViiV healthcare) for once monthly administration by intramuscular route...Moreover, it expatiates on application of profuse nanoformulations for long-acting effect with promising preclinical discoveries and two clinical leads. To add on, utilization of physiology- based and mechanism-based pharmacokinetic modelling and in vivo animal models which could lead to enhanced safety and efficacy of LA nanoformulations in humans have been included.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa. (Pubmed Central) -  Jun 22, 2021   
    To add on, utilization of physiology- based and mechanism-based pharmacokinetic modelling and in vivo animal models which could lead to enhanced safety and efficacy of LA nanoformulations in humans have been included. No abstract available
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    How about Cabenuva? (Twitter) -  Jun 2, 2021   
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  First Extended-Release Injectable Drug Therapy for HIV. (Pubmed Central) -  May 11, 2021   
    These results demonstrate the durability of CAB+RPV LA as a well-tolerated, effective maintenance therapy. Cabenuva-an injectable formulation of cabotegravir and rilpivirine and the first injectable complete therapy for adults with HIV-1-is now approved.It is administered once a month as two intramuscular injections following a month of treatment with the oral forms of these drugs.
  • ||||||||||  Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial completion date, Trial primary completion date:  More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) -  May 6, 2021   
    P1/2,  N=155, Active, not recruiting, 
    Cabenuva-an injectable formulation of cabotegravir and rilpivirine and the first injectable complete therapy for adults with HIV-1-is now approved.It is administered once a month as two intramuscular injections following a month of treatment with the oral forms of these drugs. Trial completion date: Apr 2026 --> Jul 2025 | Trial primary completion date: May 2022 --> Dec 2022
  • ||||||||||  Clinical, Review, Journal:  Risks and benefits of reducing the number of drugs to treat HIV-1 infection. (Pubmed Central) -  Apr 30, 2021   
    Some two-drug regimens, especially those including maraviroc, have not been as successful. Long-term safety issues of these two-drug regimens remain to be determined, but with the overwhelming evidence available in virological control and short-term safety compared to three-drug regimens, the potential benefits of some of these two-drug regimens appear to outweigh the risks.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    New trial:  Cabenuva Injection Tracking in CHORUS (clinicaltrials.gov) -  Apr 27, 2021   
    P=N/A,  N=43, Enrolling by invitation, 
  • ||||||||||  Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    [VIRTUAL] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS () -  Mar 18, 2021 - Abstract #CROI2021CROI_715;    
    Since InSTI-associated weight changes have only recently emerged, collection of weight data across the CAB development program was not standardized at sites and limited metabolic data were collected. Future and on-going studies will further characterize potential InSTI-associated weight gain and metabolic perturbations.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Review, Journal:  Cabotegravir Plus Rilpivirine: First Approval. (Pubmed Central) -  Jan 2, 2021   
    Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the treatment of HIV-1 infection in adults to replace current antiretroviral therapy in patients who are virologically stable and suppressed. This article summarizes the milestones in the development of co-packaged cabotegravir and rilpivirine leading to this first approval.